Interpreting Lenvatinib Plus Pembrolizumab Data in Frontline RCC

The CLEAR trial established lenvatinib plus pembrolizumab as a frontline option in advanced RCC. Interpreting its results alongside other pivotal studies requires close attention to the populations enrolled, and the panel examines how differences in baseline characteristics may shape apparent efficacy. Faculty note that CLEAR enrolled a larger share of patients with favorable-risk disease and fewer with poor-risk disease than other contemporary trials. That mix may have contributed to its high response rates and lengthy progression-free survival. They also explain how practice changes after the cytoreductive nephrectomy trials meant more patients entered with the primary tumor still in place. The discussion addresses the pitfalls of cross-trial comparison and whether the lenvatinib-based combination remains appropriate for patients with high-risk metastatic sites. Faculty point to early and sustained separation of survival curves in patients with bone and visceral metastases, including liver involvement, which supports its use in these prognostically challenging subgroups.